Although posaconazole is approved for the prophylaxes and treatment of invasive fungal
infections, specific dosing guidelines for posaconazole in (morbidly) obese patients are not
specified. There is clear evidence indicating that heavier patients are receiving a
sub-optimal dose if the current guidelines are used. Specifically in the setting of augmented
prevalence of species with intermediate susceptible to posaconazole, adequate dosing is
needed at start of treatment.
Therefore it seems prudent to conduct a trial in a cohort of obese patients who receive
posaconazole (300mg or 400mg) and define the pharmacokinetics. These will then be compared to
the pharmacokinetics in a normal-weight group receiving 300mg posaconazole.